Strategy to Improve the Oral Pharmacokinetics of Cyclin-Dependent Kinase 4/6 Inhibitors: Enhancing Permeability and CYP450 Inhibition by a Natural Bioenhancer
AAPS PharmSciTech · 2024
DOI: 10.1208/s12249-024-02899-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift AAPS PharmSciTech, 2024. Verfasst von Prajakta Harish Patil und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, 576104, Karnataka, …. Hauptthemen laut MEDLINE: Biological Availability, Cyclin-Dependent Kinase 6, Flavanones, Protein Kinase Inhibitors. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Manipal Academy of Higher Education, Manipal.
Abstract (Originalsprache)
Palbociclib and ribociclib an orally bioavailable, potent cyclin-dependent kinase 4/6 inhibitors, with low oral bioavailability due to substrate specificity towards CYP3A and P-glycoprotein. Thus, current research aims to examine the effect of a bioenhancer (naringin), on oral pharmacokinetics of palbociclib and ribociclib. Naringin’s affinity for CYP3A4 and P-glycoprotein was studied using molecular docking; its impact on palbociclib/ribociclib CYP3A metabolism and P-glycoprotein-mediated efflux was examined using in vitro preclinical models; and its oral pharmacokinetics in rats were assessed following oral administration of palbociclib/ribociclib in presence of naringin (50 and 100 mg/kg). Naringin binds optimally to both proteins with the highest net binding energy of − 1477.23 and − 1607.47 kcal/mol, respectively. The microsomal intrinsic clearance of palbociclib and ribociclib was noticeably reduced by naringin (5–100 µM), by 3.0 and 2.46-folds, respectively. Similarly, naringin had considerable impact on the intestinal transport and efflux of both drugs. The pre-treatment with 100 mg/kg naringin increased significantly ( p < 0.05) the oral exposure of palbociclib (2.0-fold) and ribociclib (1.95-fold). Naringin's concurrent administration of palbociclib and ribociclib increased their oral bioavailability due to its dual inhibitory effect on CYP3A4 and P-glycoprotein; thus, concurrent naringin administration may represent an innovative strategy for enhancing bioavailability of cyclin-dependent kinase inhibitors. Graphical Abstract
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Chemistry, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, 576104, Karnataka, India.
- Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, 576104, Karnataka, India.
- Department of Pharmaceutical Chemistry, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, 576104, Karnataka, India. jagadish.pc@manipal.edu.
Förderung
- Manipal Academy of Higher Education, Manipal
Zitieren
APA
Patil, P. H., Desai, M. P., Rao, R. R., Mutalik, S., & Puralae Channabasavaiah, J. (2024). Strategy to Improve the Oral Pharmacokinetics of Cyclin-Dependent Kinase 4/6 Inhibitors: Enhancing Permeability and CYP450 Inhibition by a Natural Bioenhancer. AAPS PharmSciTech. https://doi.org/10.1208/s12249-024-02899-3
Vancouver
Patil PH, Desai MP, Rao RR, Mutalik S, Puralae Channabasavaiah J. Strategy to Improve the Oral Pharmacokinetics of Cyclin-Dependent Kinase 4/6 Inhibitors: Enhancing Permeability and CYP450 Inhibition by a Natural Bioenhancer. AAPS PharmSciTech. 2024. doi:10.1208/s12249-024-02899-3
BibTeX
@article{Patil2024,
author = {Patil, Prajakta Harish and Desai, Mrunal Pradeep and Rao, Rajat Radhakrishna and Mutalik, Srinivas and Puralae Channabasavaiah, Jagadish},
title = {Strategy to Improve the Oral Pharmacokinetics of Cyclin-Dependent Kinase 4/6 Inhibitors: Enhancing Permeability and CYP450 Inhibition by a Natural Bioenhancer},
journal = {AAPS PharmSciTech},
year = {2024},
doi = {10.1208/s12249-024-02899-3}
}
EUVIMED